PL2459224T3 - Koniugaty białka związanego z krzepnięciem krwi - Google Patents
Koniugaty białka związanego z krzepnięciem krwiInfo
- Publication number
- PL2459224T3 PL2459224T3 PL10738119T PL10738119T PL2459224T3 PL 2459224 T3 PL2459224 T3 PL 2459224T3 PL 10738119 T PL10738119 T PL 10738119T PL 10738119 T PL10738119 T PL 10738119T PL 2459224 T3 PL2459224 T3 PL 2459224T3
- Authority
- PL
- Poland
- Prior art keywords
- blood coagulation
- protein conjugates
- coagulation protein
- conjugates
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22882809P | 2009-07-27 | 2009-07-27 | |
US34713610P | 2010-05-21 | 2010-05-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2459224T3 true PL2459224T3 (pl) | 2017-08-31 |
Family
ID=52845847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL10738119T PL2459224T3 (pl) | 2009-07-27 | 2010-07-26 | Koniugaty białka związanego z krzepnięciem krwi |
Country Status (11)
Country | Link |
---|---|
US (3) | US10350301B2 (pl) |
EP (1) | EP3093029A1 (pl) |
JP (7) | JP2015227385A (pl) |
CN (2) | CN106110311A (pl) |
ES (1) | ES2856055T3 (pl) |
HU (1) | HUE028056T2 (pl) |
NZ (1) | NZ623810A (pl) |
PL (1) | PL2459224T3 (pl) |
PT (1) | PT2459224T (pl) |
RU (2) | RU2744370C2 (pl) |
SG (1) | SG10201401194VA (pl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2744370C2 (ru) * | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
CN109293780B (zh) * | 2018-09-04 | 2021-05-07 | 厦门宏谱福生物科技有限公司 | 一种人组织因子凝血复合物及其制备方法 |
CN109541115B (zh) * | 2018-11-28 | 2021-04-20 | 西北大学 | 唾液酸化糖链同分异构体的高分辨顺序分离和准确定量分析方法 |
US11767526B2 (en) | 2019-01-23 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
JP2022519586A (ja) * | 2019-02-04 | 2022-03-24 | ゼネティック バイオサイエンシーズ インコーポレイテッド | 糖ポリシアル酸化治療用タンパク質を使用する方法 |
US20230133656A1 (en) * | 2019-07-03 | 2023-05-04 | Molly Sandra Shoichet | Hydrogel compositions and uses thereof |
AU2022226164A1 (en) | 2021-02-26 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA647314A (en) | 1962-08-21 | J. Lewis Richard | Tire tool | |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
US4847325A (en) * | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US5153265A (en) | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
US4966999A (en) | 1988-06-07 | 1990-10-30 | Cytogen Corporation | Radiohalogenated compounds for site specific labeling |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
SE466754B (sv) | 1990-09-13 | 1992-03-30 | Berol Nobel Ab | Saett att kovalent binda biopolymerer till hydrofila ytor |
US5492821A (en) | 1990-11-14 | 1996-02-20 | Cargill, Inc. | Stabilized polyacrylic saccharide protein conjugates |
WO1992016555A1 (en) | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
GB9112212D0 (en) * | 1991-06-06 | 1991-07-24 | Gregoriadis Gregory | Pharmaceutical compositions |
US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
AU5098193A (en) | 1992-09-01 | 1994-03-29 | Berlex Laboratories, Inc. | Glycolation of glycosylated macromolecules |
WO1994007510A1 (en) | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
NO934477L (no) * | 1992-12-09 | 1994-06-10 | Ortho Pharma Corp | PEG hydrazon- og PEG oksim-bindingdannende reagenser og proteinderivater derav |
NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5298643A (en) | 1992-12-22 | 1994-03-29 | Enzon, Inc. | Aryl imidate activated polyalkylene oxides |
WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
WO1994028024A1 (en) * | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
WO1996040731A1 (en) | 1995-06-07 | 1996-12-19 | Mount Sinai School Of Medicine Of The City University Of New York | Pegylated modified proteins |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
CA2262994A1 (en) * | 1996-08-02 | 1998-02-12 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
AU7266898A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US6183738B1 (en) | 1997-05-12 | 2001-02-06 | Phoenix Pharamacologics, Inc. | Modified arginine deiminase |
US20020160948A1 (en) | 1998-07-21 | 2002-10-31 | Aprile Pilon | Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions |
WO1998055607A2 (en) | 1997-06-04 | 1998-12-10 | Oxford Biomedica (Uk) Limited | Tumor targeted vector |
WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
ES2252876T5 (es) | 1997-12-03 | 2014-04-03 | Roche Diagnostics Gmbh | Proceso para preparar polipéptidos con glicolización adecuada |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
DE19829289C2 (de) | 1998-06-30 | 2001-12-06 | Siemens Ag | Verfahren zur Berechnung der Koeffizienten eines nichtrekursiven digitalen Filters |
CN1330675A (zh) | 1998-08-28 | 2002-01-09 | 格莱风科学公司 | 精确长度的聚酰胺链、其制备方法和其与蛋白质的缀合物 |
ES2630278T3 (es) | 1998-10-16 | 2017-08-21 | Biogen Ma Inc. | Conjugados poliméricos de interferón beta-1a y usos de los mismos |
DE19852729A1 (de) | 1998-11-16 | 2000-05-18 | Werner Reutter | Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung |
CN100553678C (zh) | 1999-02-22 | 2009-10-28 | 巴克斯特国际有限公司 | 新的无白蛋白的因子ⅷ制剂 |
WO2000075105A1 (en) * | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
US6697436B1 (en) | 1999-07-13 | 2004-02-24 | Pmc-Sierra, Inc. | Transmission antenna array system with predistortion |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
YU32402A (sh) | 1999-11-12 | 2005-03-15 | Maxygen Holdings Ltd. | Konjugati gama interferona |
US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
US6586398B1 (en) | 2000-04-07 | 2003-07-01 | Amgen, Inc. | Chemically modified novel erythropoietin stimulating protein compositions and methods |
EP1282693B1 (en) | 2000-05-03 | 2010-10-20 | Novo Nordisk Health Care AG | Human coagulation factor vii variants |
AU2001256148A1 (en) | 2000-05-03 | 2001-11-12 | Novo-Nordisk A/S | Subcutaneous administration of coagulation factor vii |
WO2001087922A2 (en) | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
AU2001268228A1 (en) | 2000-06-08 | 2001-12-17 | La Jolla Pharmaceutical Company | Multivalent platform molecules comprising high molecular weight polyethylene oxide |
US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
HUP0301246A3 (en) | 2000-09-13 | 2005-12-28 | Novo Nordisk Healthcare Ag | Human coagulation factor vii variants |
BR0114374A (pt) | 2000-10-02 | 2003-12-30 | Novo Nordisk As | Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação |
US7001994B2 (en) * | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
EP1373493B1 (en) | 2001-03-22 | 2013-07-31 | Novo Nordisk Health Care AG | Coagulation factor vii derivative |
JP2005512512A (ja) | 2001-07-05 | 2005-05-12 | インサイト・ゲノミックス・インコーポレイテッド | 分泌タンパク質 |
US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
US7265085B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
NZ532027A (en) | 2001-10-10 | 2008-09-26 | Neose Technologies Inc | Remodeling and glycoconjugation of peptides |
US7026440B2 (en) | 2001-11-07 | 2006-04-11 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
EP1461445B1 (en) | 2001-11-28 | 2008-08-20 | Neose Technologies, Inc. | Glycoprotein remodeling using endoglycanases |
CA2468230A1 (en) | 2001-11-28 | 2003-06-05 | Neose Technologies, Inc. | Glycopeptide remodeling using amidases |
DK1517710T3 (da) | 2002-06-21 | 2011-07-18 | Novo Nordisk Healthcare Ag | Pegylerede faktor VII-glycoformer |
DE10228657A1 (de) | 2002-06-27 | 2004-01-15 | Celanese Ventures Gmbh | Protonenleitende Membran und deren Verwendung |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
BR0314107A (pt) * | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Método de produção de derivados de hidroxialquil amido |
EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
DE02020425T1 (de) * | 2002-09-11 | 2004-07-15 | Fresenius Kabi Deutschland Gmbh | Hasylierte Polypeptide, besonders hasyliertes Erythropoietin |
US20040062748A1 (en) | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
CA2509260C (en) | 2002-12-31 | 2012-10-02 | Nektar Therapeutics Al, Corporation | Maleamic acid polymer derivatives and their bioconjugates |
US7432330B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
SI1596887T1 (sl) | 2003-02-26 | 2022-05-31 | Nektar Therapeutics | Konjugati polimer-del faktorja VIII |
KR20060003862A (ko) * | 2003-03-14 | 2006-01-11 | 네오스 테크놀로지스, 인크. | 수용성분기폴리머 및 그 접합체 |
CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
WO2006127896A2 (en) | 2005-05-25 | 2006-11-30 | Neose Technologies, Inc. | Glycopegylated factor ix |
DE10330674B4 (de) | 2003-07-08 | 2007-01-11 | Eppendorf Ag | Zellbehandlungskammer |
EP1653991A2 (en) * | 2003-08-08 | 2006-05-10 | Fresenius Kabi Deutschland GmbH | Conjugates of a polymer and a protein linked by an oxime linking group |
WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
CN1832762B (zh) * | 2003-08-08 | 2012-09-05 | 弗雷泽纽斯卡比德国有限公司 | 羟烷基淀粉与g-csf的偶联物 |
JP2007501812A (ja) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | ペプチドのための結合剤として新しい構造上十分に定義された枝分れしたポリマーの合成および適用 |
JP2007501870A (ja) * | 2003-08-08 | 2007-02-01 | フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒドロキシアルキルデンプンとg−csfの複合体 |
JP2007501888A (ja) * | 2003-08-12 | 2007-02-01 | リポクセン テクノロジーズ リミテッド | ポリシアル酸誘導体 |
WO2005016974A1 (en) | 2003-08-12 | 2005-02-24 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US20070254836A1 (en) | 2003-12-03 | 2007-11-01 | Defrees Shawn | Glycopegylated Granulocyte Colony Stimulating Factor |
WO2005055950A2 (en) | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Glycopegylated factor ix |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
CA2549295C (en) * | 2003-12-04 | 2016-05-03 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
KR101439880B1 (ko) | 2004-01-08 | 2014-09-12 | 라티오팜 게엠베하 | 펩티드의 오-결합형 글리코실화 |
AU2005209303A1 (en) * | 2004-01-29 | 2005-08-11 | Biosynexus, Inc. | Use of amino-oxy functional groups in the preparation of vaccines conjugates |
GB0412291D0 (en) | 2004-06-02 | 2004-07-07 | Enersys Ltd | A battery |
RU2276123C2 (ru) | 2004-07-06 | 2006-05-10 | Центральный научно-исследовательский институт геологии нерудных полезных ископаемых (ЦНИИгеолнеруд) | Способ получения комплексного минерального удобрения |
US20090292110A1 (en) | 2004-07-23 | 2009-11-26 | Defrees Shawn | Enzymatic modification of glycopeptides |
JP2008507990A (ja) | 2004-08-02 | 2008-03-21 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Fviiの抱合体 |
CN101039965A (zh) * | 2004-08-12 | 2007-09-19 | 利普生技术有限公司 | 唾液酸衍生物 |
US8652334B2 (en) * | 2004-08-12 | 2014-02-18 | Lipoxen Technologies Limited | Fractionation of charged polysaccharide |
WO2006016168A2 (en) * | 2004-08-12 | 2006-02-16 | Lipoxen Technologies Limited | Sialic acid derivatives |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
PL1824988T3 (pl) | 2004-11-12 | 2018-01-31 | Bayer Healthcare Llc | Ukierunkowana na miejsce modyfikacja czynnika VIII |
MX2007007877A (es) | 2004-12-27 | 2007-08-21 | Baxter Int | Conjugados de polimero-factor de von willebrand. |
JP2008526864A (ja) | 2005-01-06 | 2008-07-24 | ネオス テクノロジーズ インコーポレイテッド | 糖断片を用いる糖結合 |
US8217154B2 (en) * | 2005-02-23 | 2012-07-10 | Lipoxen Technologies Limited | Activated sialic acid derivatives for protein derivatisation and conjugation |
PL1877099T3 (pl) * | 2005-04-06 | 2013-02-28 | Genzyme Corp | Terapeutyczne koniugaty zawierające enzym lizosomalny, kwas polisialowy i grupę kierującą |
EP2279758B1 (en) | 2005-06-16 | 2015-02-25 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも1つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
TW200719470A (en) | 2005-07-11 | 2007-05-16 | Sharp Kk | Variable resistance device |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
US20090017007A1 (en) | 2005-08-26 | 2009-01-15 | Maxygen Holdings Ltd. | Liquid factor vii composition |
JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 viii |
EP2089052A4 (en) | 2006-05-24 | 2011-02-16 | Peg Biosciences | POLYETHYLENE GLYCOL-BASED LINK COMPOUNDS AND BIOLOGICALLY ACTIVE CONJUGATES BASED ON SAID COMPOUNDS |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
US8097437B2 (en) | 2006-07-13 | 2012-01-17 | Serum Institute Of India Ltd. | Highly pure polysialic acid and process for preparation thereof |
US8394921B2 (en) * | 2006-07-25 | 2013-03-12 | Lipoxen Technologies Limited | N-terminal derivatisation of proteins with polysaccharides |
EP2059527B1 (en) * | 2006-09-01 | 2014-12-03 | Novo Nordisk Health Care AG | Modified glycoproteins |
EP2054521A4 (en) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES |
BRPI0720282B8 (pt) * | 2006-12-15 | 2021-05-25 | Baxalta GmbH | construção proteica, composição farmacêutica, e, kit |
EP2099475B1 (en) | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subcutaneous administration of coagulation factor viia-related polypeptides |
SI2457919T1 (sl) * | 2007-01-18 | 2019-10-30 | Genzyme Corp | Oligosaharidi, ki vsebujejo skupino aminooksi in njihovi konjugati |
WO2008119815A1 (en) | 2007-04-02 | 2008-10-09 | Novo Nordisk A/S | Subcutaneous administration of coagulation factor ix |
WO2009000522A1 (en) * | 2007-06-26 | 2008-12-31 | Baxter International Inc. | Hydrolysable polymeric fmoc-linker |
CA2690440A1 (en) | 2007-07-03 | 2009-01-08 | Children's Hospital & Research Center At Oakland | Oligosialic acid derivatives, methods of manufacture, and immunological uses |
US20100239517A1 (en) | 2007-10-09 | 2010-09-23 | Stephen Brocchini | Novel conjugated proteins and peptides |
EP2930182A1 (en) * | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
NZ588854A (en) | 2008-04-24 | 2011-12-22 | Celtic Pharma Peg Ltd | Factor ix-polyethylene conjugates with extended half-lives |
WO2009141418A1 (en) | 2008-05-23 | 2009-11-26 | Novo Nordisk A/S | Formulations of peg-functionalised serine proteases with high concentrations of an aromatic preservative |
EP2285401A1 (en) | 2008-05-23 | 2011-02-23 | Novo Nordisk Health Care AG | Low viscosity compositions comprising a pegylated gla-domain containing protein |
US20110286988A1 (en) | 2008-06-04 | 2011-11-24 | Bayer Healthcare Llc | FVIII Muteins for Treatment of Von Willebrand Disease |
ES2536882T3 (es) | 2008-07-21 | 2015-05-29 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
WO2010045568A1 (en) * | 2008-10-17 | 2010-04-22 | Baxter International Inc. | Modified blood factors comprising a low degree of water soluble polymer |
CA2740793A1 (en) | 2008-11-03 | 2010-06-03 | Haiyan Jiang | Method for the treatment of hemophilia |
US20120121613A1 (en) | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
WO2010102886A1 (en) | 2009-02-19 | 2010-09-16 | Novo Nordisk A/S | Modification of factor viii |
US9005598B2 (en) | 2009-03-04 | 2015-04-14 | Polytherics Limited | Conjugated proteins and peptides |
US20100330033A1 (en) | 2009-04-16 | 2010-12-30 | Nian Wu | Protein-carrier conjugates |
GB0908393D0 (en) | 2009-05-15 | 2009-06-24 | Almac Sciences Scotland Ltd | Labelling method |
RU2744370C2 (ru) * | 2009-07-27 | 2021-03-05 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
ES2597954T3 (es) * | 2009-07-27 | 2017-01-24 | Baxalta GmbH | Conjugados de proteína de la coagulación sanguínea |
EP2459226B1 (en) | 2009-07-27 | 2016-06-29 | Lipoxen Technologies Limited | Glycopolysialylation of proteins other than blood coagulation proteins |
EA201290069A1 (ru) | 2009-07-31 | 2012-07-30 | Байер Хелскер Ллс | Модифицированные полипептиды фактора ix и их применения |
DE102009028526A1 (de) | 2009-08-13 | 2011-02-24 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Verfahren zur Modifikation und Funktionalisierung von Sacchariden |
US20120178914A1 (en) | 2009-09-25 | 2012-07-12 | Vybion, Inc. | Polypeptide modification |
CN102639553A (zh) | 2009-11-24 | 2012-08-15 | 诺沃—诺迪斯克保健股份有限公司 | 纯化聚乙二醇化蛋白质的方法 |
WO2011101242A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
EP2640483A1 (en) | 2010-11-15 | 2013-09-25 | Biogen Idec Inc. | Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography |
EP2729161B1 (en) | 2011-07-08 | 2018-12-19 | Bioverativ Therapeutics Inc. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
-
2010
- 2010-07-26 RU RU2016121611A patent/RU2744370C2/ru active
- 2010-07-26 PL PL10738119T patent/PL2459224T3/pl unknown
- 2010-07-26 CN CN201610586352.9A patent/CN106110311A/zh active Pending
- 2010-07-26 CN CN201410737723.XA patent/CN104530182A/zh active Pending
- 2010-07-26 ES ES16168473T patent/ES2856055T3/es active Active
- 2010-07-26 PT PT107381196T patent/PT2459224T/pt unknown
- 2010-07-26 NZ NZ623810A patent/NZ623810A/en not_active IP Right Cessation
- 2010-07-26 HU HUE10738119A patent/HUE028056T2/en unknown
- 2010-07-26 SG SG10201401194VA patent/SG10201401194VA/en unknown
- 2010-07-26 EP EP16165650.9A patent/EP3093029A1/en active Pending
-
2014
- 2014-06-06 RU RU2014123260A patent/RU2662807C2/ru active
-
2015
- 2015-09-15 JP JP2015182155A patent/JP2015227385A/ja active Pending
-
2016
- 2016-03-02 JP JP2016040490A patent/JP6208269B2/ja active Active
- 2016-08-29 US US15/249,657 patent/US10350301B2/en active Active
-
2017
- 2017-09-06 JP JP2017171508A patent/JP2018024882A/ja active Pending
- 2017-09-18 US US15/707,844 patent/US10772968B2/en active Active
- 2017-11-10 JP JP2017217408A patent/JP7071093B2/ja active Active
-
2019
- 2019-06-20 US US16/447,134 patent/US11040109B2/en active Active
- 2019-11-08 JP JP2019203576A patent/JP2020037701A/ja active Pending
-
2020
- 2020-11-27 JP JP2020197666A patent/JP2021042244A/ja active Pending
-
2022
- 2022-02-07 JP JP2022017047A patent/JP2022058911A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG10201401194VA (en) | 2014-07-30 |
US10350301B2 (en) | 2019-07-16 |
CN106110311A (zh) | 2016-11-16 |
JP2015227385A (ja) | 2015-12-17 |
US20180200380A1 (en) | 2018-07-19 |
RU2016121611A3 (pl) | 2019-12-10 |
JP2018024882A (ja) | 2018-02-15 |
JP6208269B2 (ja) | 2017-10-04 |
JP2022058911A (ja) | 2022-04-12 |
JP2016113626A (ja) | 2016-06-23 |
HUE028056T2 (en) | 2016-11-28 |
US20160361430A1 (en) | 2016-12-15 |
JP2020037701A (ja) | 2020-03-12 |
JP7071093B2 (ja) | 2022-05-18 |
JP2021042244A (ja) | 2021-03-18 |
NZ623810A (en) | 2015-10-30 |
RU2744370C2 (ru) | 2021-03-05 |
EP3093029A1 (en) | 2016-11-16 |
US11040109B2 (en) | 2021-06-22 |
RU2662807C2 (ru) | 2018-07-31 |
US10772968B2 (en) | 2020-09-15 |
RU2016121611A (ru) | 2018-11-29 |
RU2014123260A (ru) | 2015-12-20 |
EP3093029A8 (en) | 2016-12-28 |
CN104530182A (zh) | 2015-04-22 |
PT2459224T (pt) | 2016-09-05 |
ES2856055T3 (es) | 2021-09-27 |
US20190314516A1 (en) | 2019-10-17 |
JP2018035192A (ja) | 2018-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1171691A1 (zh) | 血液凝結蛋白綴合物 | |
HK1249580A1 (zh) | 使用納米造孔儀的蛋白質檢測 | |
HK1218558A1 (zh) | 蛋白 | |
HK1163569A1 (en) | Processing blood | |
PL2459224T3 (pl) | Koniugaty białka związanego z krzepnięciem krwi | |
ZA201200200B (en) | Chimaeric protein | |
PL2467078T3 (pl) | Kleszcze elektrochirurgiczne | |
ZA201208989B (en) | Conjugated blood coagulation factor viii | |
GB0816976D0 (en) | Protein | |
ZA201109283B (en) | Protein | |
ZA201107630B (en) | Blood parasiticide | |
IL207593A0 (en) | Blood substitute solution | |
GB0908788D0 (en) | Tissue analysis | |
GB0922384D0 (en) | 68GA-labled human serum albumin | |
SI2459224T1 (sl) | Konjugati krvnega koagulacijskega proteina | |
HK1176015A1 (en) | Therapeutic use of protein polymer conjugates | |
GB2462726B (en) | Protein expression | |
GB0818627D0 (en) | Protein | |
GB0914470D0 (en) | Blood coagulation factors | |
GB0904491D0 (en) | Blood coagulation factors | |
GB0902222D0 (en) | Protein expression | |
GB0909384D0 (en) | Protein | |
GB0921430D0 (en) | Protein for therapeutic use | |
GB0811893D0 (en) | Protein expression | |
AU2009905146A0 (en) | Blood flash needle |